Drug Shortage Report for NOVAMOXIN
| Report ID | 172263 |
| Drug Identification Number | 01934163 |
| Brand name | NOVAMOXIN |
| Common or Proper name | NOVAMOXIN |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | AMOXICILLIN |
| Strength(s) | 250MG |
| Dosage form(s) | GRANULES FOR SUSPENSION |
| Route of administration | ORAL ORAL |
| Packaging size | 100 |
| ATC code | J01CA |
| ATC description | BETA-LACTAM ANTIBACTERIALS, PENICILLINS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-08-20 |
| Estimated end date | 2023-07-10 |
| Actual end date | 2023-07-04 |
| Shortage status | Resolved |
| Updated date | 2024-02-14 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.